You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The researchers used a yeast-based synthetic genomics platform to engineer and resurrect chemically synthesized clones of the SARS-CoV-2 virus in only a week.
The company — formerly called Expedeon — recently divested its proteomics and immunology businesses in order to focus on the manufacture and supply of synthetic DNA.
The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.
The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.